ZIMLAB share price & delivery %

Filings & corporate actions

15 results filed

CSV

Next results · Q2 FY27

Expected 1 Nov 2026 – 12 Nov 2026

Estimate: filed 32–43 days after quarter end, last 3 times

2026

6 AugresultsResults · Q1 FY27 · consolidated and standalone-2.8%NSE
17 JulshareholdingShareholding · 30 Jun 2026-1.6%NSE
19 MayresultsResults · Q4 FY26 · consolidated and standalone-1.5%NSE
18 AprshareholdingShareholding · 31 Mar 2026+0.5%NSE
17 MarshareholdingShareholding · 13 Mar 2026+9.6%NSE
11 FebresultsResults · Q3 FY26 · consolidated and standalone-2.2%NSE
13 JanshareholdingShareholding · 31 Dec 2025+3.4%NSE

Reaction to results · all yearsrose on day 0 in 3 of 15 CSV

Quarter	Filed	Day 0	+5D	+20D	Rel vol
Q1 FY27	6 Aug 2026	-2.8%	-6.6%	+9.0%	2.0×
Q4 FY26	19 May 2026	-1.5%	+1.5%	+13.3%	0.7×
Q3 FY26	11 Feb 2026	-2.2%	-7.5%	-13.1%	1.4×
Q2 FY26	12 Nov 2025	-4.3%	-4.4%	-2.3%	0.4×
Q1 FY26	7 Aug 2025	-4.5%	-10.9%	-7.8%	0.3×
Q4 FY25	21 May 2025	+3.4%	+0.7%	+19.1%	1.1×
Q3 FY25	10 Feb 2025	-5.0%	-8.1%	-20.8%	0.7×
Q2 FY25	9 Nov 2024	-5.9%	-8.5%	-0.2%	0.9×
Q1 FY25	3 Aug 2024	-3.8%	-6.0%	+4.9%	2.4×
Q4 FY24	13 May 2024	-1.5%	-5.9%	-13.9%	1.1×
Q3 FY24	29 Jan 2024	-1.2%	+1.1%	+2.6%	0.8×
Q2 FY24	1 Nov 2023	+3.4%	+2.5%	-0.9%	1.9×
Q1 FY24	14 Aug 2023	-6.5%	+2.2%	-4.7%	1.7×
Q4 FY23	19 May 2023	-5.0%	-4.1%	+11.7%	2.5×
Q3 FY23	3 Feb 2023	+0.9%	-3.7%	+1.5%	2.1×
Average		-2.4%	-3.8%	-0.1%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV

Revenue YoY+31.2%

Profit YoY—

Interest cost YoY+14.4%

Revenue QoQ-10.5%

Profit QoQ-207.4%

CAGR	2Y	3Y	4Y	5Y	6Y	7Y
Revenue	+1.9%	—	—	—	—	—
Profit	-54.6%	—	—	—	—	—

Key data

CSV

Open139.00

Day range135.59 – 140.00

52-week range59.31 – 144.49

From 52w high-4.1%

RSI (14)60.2

ATR (14)7.40

Volume63.6K

Avg volume (20D)1.32L

Rel volume0.48×

Volatility (1Y)49.8%

Turnover₹88.2L

SMA 50 / 200124.79 / 96.52

Delivery percentage

Latest · 6 Oct 202656.6%

20-day avg51.4%

1-year avg71.0%

Percentile (own history)44th

Range11.7–100.0%

Sessions958

Over the last 20 sessions ZIMLAB settled 51.4% of its traded quantity, which is above average for an NSE equity. Its one-year average is 71.0%, so recent sessions are running 19.6 points lower than usual. The latest session ranks higher than 44% of the 958 sessions on record for it.

What delivery percentage measures Scan the whole market on delivery

IndustryPharmaceuticals

PeersDIVISLAB LAURUSLABS SUNPHARMA WOCKPHARMA DRREDDY MOREPENLAB

Performance returns

CSV

	1D	1W	1M	3M	6M	1Y
Price	+1.07%	+0.74%	+8.24%	+14.81%	+105.38%	+89.23%

Valuation

CSV

Market cap₹744 Cr

P/E (TTM)201.2

EPS (TTM)0.69

Shares outstanding5.35Cr

Listed25 Nov 2022

Ownership

CSV

Promoter30.36%

Promoter Δ QoQ+0.01 pp

Public69.64%

FII0.03%

DII1.33%

Pledged0.00%

Quarterly results · consolidated

CSV

	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue (₹ Cr)	88.7	108.7	105.3	94.2
YoY chg	-3.7%	+12.8%	-3.2%	+31.2%
Net profit (₹ Cr)	(0.4)	4.4	3.7	(4.0)
YoY chg	-117.8%	+9.9%	-23.4%	—
Net margin	-0.5%	4.0%	3.6%	-4.3%
EPS	-0.09	0.90	0.76	-0.75

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 30.36% · public 69.64%

2022-092026-06

Promoter
Public and others

Promoter: 30.36%
Public: 69.64%
Promoter change: +0.01 pp
Filed: 17 Jul 2026

FII: 0.03%
DII: 1.33%
Promoter pledged: 0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV

₹ crore, as filed

	Q2 FY24	Q3 FY24	Q4 FY24^A	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue from operations	85.8	96.3	117.9	81.8	92.1	96.3	108.7	71.8	88.7	108.7	105.3	94.2
Other income	1.4	1.1	1.5	1.0	1.3	1.8	1.7	1.5	2.0	1.7	6.2	1.0
Total income	87.2	97.4	119.4	82.8	93.5	98.1	110.4	73.2	90.8	110.4	111.4	95.2
Total expenses	81.8	90.4	108.4	81.6	90.5	92.4	102.3	75.7	91.1	104.3	106.5	100.7
└ Finance costs	1.2	1.7	2.3	2.9	2.9	2.7	2.9	3.3	3.2	3.4	3.3	3.6
└ Depreciation	4.1	3.9	3.9	4.9	5.0	4.9	5.3	4.9	5.0	5.0	5.1	5.4
Profit before tax	5.4	7.0	11.0	1.2	3.0	5.7	8.1	(2.4)	(0.3)	6.0	4.9	(5.6)
Tax expense	1.3	2.2	2.9	0.3	0.6	1.7	3.2	(0.6)	0.1	1.6	1.2	(1.6)
Net profit	4.1	4.8	8.1	0.9	2.4	4.0	4.9	(1.9)	(0.4)	4.4	3.7	(4.0)
EPS	0.85	0.98	1.66	0.18	0.49	0.82	1.01	-0.38	-0.09	0.90	0.76	-0.75
Net margin	4.83%	4.97%	6.86%	1.10%	2.58%	4.15%	4.49%	-2.61%	-0.48%	4.05%	3.55%	-4.27%
PBT margin	6.34%	7.28%	9.33%	1.51%	3.22%	5.92%	7.46%	-3.39%	-0.39%	5.56%	4.69%	-5.92%
Tax rate	23.77%	31.79%	26.49%	27.23%	19.63%	29.86%	39.76%	—	—	27.27%	24.32%	—

^A audited · ^R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 6 Aug 2026.

ZIMLAB at a glance

ZIMLAB closed at ₹138.57 on 6 Oct 2026, +1.07% on the day, +89.2% over one year, 4.1% below its 52-week high of ₹144.49.
Delivery was 56.6% of traded quantity on 6 Oct 2026, the 44th percentile of its own 958 sessions with a reading (20-session average 51.4%, 1-year average 71.0%).
Market capitalisation is ₹744 crore at a trailing P/E of 201.2 (trailing EPS ₹0.69).
Q1 FY27 results (consolidated, filed 6 Aug 2026): revenue ₹94 crore (+31.2% year on year), net profit ₹-4 crore; the price moved -2.8% on the first session after.
Promoters held 30.36% at 30 Jun 2026, up 0.01 percentage points on the previous filing.
Q2 FY27 results are expected between 1 Nov 2026 and 12 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV

Macro sectorHealthcare

Basic industryPharmaceuticals

ISININE518E01015

SeriesEQ

Listed25 Nov 2022

History from25 Nov 2022

Sessions958

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSE All Healthcare stocks on the NSE